VentriPoint Diagnostics

VentriPoint Diagnostics P/B

The P/B (Price-to-Book Ratio) of VentriPoint Diagnostics (VPT.V) as of Nov 22, 2026 is -5.24. In the previous year, P/B (Price-to-Book Ratio) was -7.24 — a change of -27.57% (higher).

P/B

-5.24

YoY

-27.57%

Last updated:

P/B (Price-to-Book Ratio) of VentriPoint Diagnostics is 2025 -5.24 . P/B (Price-to-Book Ratio) of VentriPoint Diagnostics was 2024 -7.24 . It decreases by -27.57% higher compared to the previous year.

The VentriPoint Diagnostics P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
-22.17 CAD
Jan 1, 2019
-8.74 CAD
Jan 1, 2020
-9.19 CAD
Jan 1, 2021
2.59 CAD
Jan 1, 2022
4.74 CAD
Jan 1, 2023
113.76 CAD
Jan 1, 2024
-7.24 CAD
Jan 1, 2025
-5.24 CAD
The VentriPoint Diagnostics P/B history
YEARP/BYoY
-5.24-27.57%
-7.24-106.36%
113.76+2,300.30%
4.74+83.02%
2.59-128.18%
-9.19+5.14%
-8.74-60.59%
-22.17+67.09%
-13.27+38.35%
-9.59-88.01%
-80.03+788.40%
-9.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

VentriPoint Diagnostics Stock analysis

What does VentriPoint Diagnostics do? VentriPoint Diagnostics Ltd. develops and commercializes diagnostic tools for heart disease monitoring, focusing on the VentriPoint Medical System (VMS+). The VMS+ uses proprietary Knowledge Based Reconstruction (KBR) technology to create 3D heart models from ultrasound, providing volume and ejection fraction measurements comparable to MRI without requiring MRI scans. The company targets healthcare providers seeking point-of-care solutions for cardiac diagnostics, particularly in cardiology departments and clinics managing heart disease patients. Its applications cover congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The company's products are sold to hospitals and medical facilities that require advanced cardiac imaging tools. VMS+ serves as a diagnostic aid that enhances ultrasound capabilities, eliminating the need for MRI in certain scenarios. The system's ability to visualize all four heart chambers and deliver MRI-equivalent metrics positions it as a cost-effective alternative for institutions aiming to reduce MRI dependency. VentriPoint Diagnostics Ltd. focuses on commercializing these diagnostic tools for heart disease monitoring across multiple clinical segments including cardiology, obstetrics, and oncology support services. VentriPoint Diagnostics Ltd. generates revenue through the sale of its diagnostic tools, specifically the VentriPoint Medical System (VMS+), to healthcare institutions. The VMS+ system is marketed as a point-of-care solution that improves cardiac diagnostics without MRI dependency. Its applications span various heart disease contexts, including congenital conditions, pregnancy-related cardiac monitoring, pulmonary hypertension, and oncology-related cardiotoxicity. The company's commercial strategy centers on providing MRI-equivalent diagnostic capabilities through ultrasound enhancement, targeting medical facilities seeking efficient and accessible cardiac imaging solutions. VentriPoint Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about VentriPoint Diagnostics stock

P/B (Price-to-Book Ratio) of VentriPoint Diagnostics is -5.24 in 2025.

P/B (Price-to-Book Ratio) of VentriPoint Diagnostics changed from -7.24 to -5.24, representing a -27.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) VentriPoint Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s VentriPoint Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — VentriPoint Diagnostics

All Key Metrics — VentriPoint Diagnostics